Indirect Comparison Between Eltrombopag & Romiplostim

Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01236014

Enrollment

Registered

2010-11-08

Start date

2009-08-31

Completion date

2009-10-31

Last updated

2017-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopaenia

Brief summary

An indirect comparison to compare the efficacy of eltrombopag versus romiplostim

Detailed description

An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

Interventions

DRUGEltrombopag

Eltrombopag & standard of care

DRUGRomiplostim

Romiplostim & standard of care

DRUGPlacebo

Placebo & standard of care

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults with ITP * Pre-specified treatment * Prospective clinical studies with at least 10 patients

Exclusion criteria

* Adults with ITP for other reasons

Design outcomes

Primary

Measure	Time frame
Durable response: platelet count of >=50 and <400 Gi/L	6 months
Overall response: either a durable response or a transient platelet response	6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026